

ClaimsSub
B3

1. A method for antigen independent activation of T cells comprising contacting T cells with a combination of cytokines.
5
2. The method of claim 1, wherein the T cells are contacted with at least two of the following:
10
 - i) interleukin-2;
 - ii) interleukin-6; and
 - iii) tumour necrosis factor α
 or functionally equivalent fragments thereof.
- 15 3. The method of claim 1 or 2, wherein the T cells are naive T cells and/or memory resting T cells.
- 20 4. The method of ^{claim} ~~any one of claims 1 to 3~~, wherein the T cells are naive CD45RA⁺ cells and/or memory resting CD45RO⁺ cells.
- 25 5. The method of ^{claim 1} ~~any one of the preceding claims~~, wherein the concentration of interleukin-2 is from 100 to 400 U/ml, the concentration of interleukin-6 is from 400 to 600 U/ml and the concentration of tumour necrosis factor α is from 15 to 35 ng/ml.
- 30 6. The method of ^{claim 1} ~~any one of the preceding claims~~, wherein the concentration of interleukin-2 is from 200 to 300 U/ml, the concentration of interleukin-6 is about 500 U/ml and the concentration of tumour necrosis factor α is about 25 ng/ml.
- 35 7. ~~The method of any one of the preceding claims, wherein T cells are activated in vitro.~~
8. A method for obtaining increased lymphokine production

002060-04202560

from a T cell culture, comprising activating the T cells using the method of claim 7.

9. The method of any one of claims 1 to 6, wherein
5 cells are activated *in vivo*.

10. The method of claim 9, wherein the activation of T cells *in vivo* leads to an enhanced immunological response.

- 10 11. A method of therapy comprising activating in a human or animal subject T cells using the method of claim ~~9~~ or 10.

Add B₄

add
B5

[illegible]